KeyCorp Raises AbCellera's Target Price to $10

Summary

KeyCorp raised AbCellera Biologics’ (NASDAQ: ABCL) target stock price from $5.00 to $10.00 while maintaining an ‘Overweight’ rating, suggesting a potential upside of 149.38% compared to the current price. Other brokerages also rated AbCellera positively, with an average target price of $8.75. AbCellera’s stock opened at $4.01, with a market cap of $1.2 billion. The company reported a quarterly loss with earnings per share (EPS) of -$0.15, exceeding expectations, although revenue did not meet expectations.Market Beat

Impact Analysis

The event is classified at the company level, focusing on AbCellera Biologics’ stock price target adjustment and ratings by KeyCorp. KeyCorp’s rating and target price increase suggest confidence in AbCellera’s future growth potential, despite its current financial challenges, such as reporting a quarterly loss. The 149.38% potential upside indicates significant investment opportunity, reflecting positive sentiment. However, investors should consider risks related to the company’s ability to meet revenue expectations. The average target price from other brokerages further supports the buy recommendation, enhancing investor confidence.Market Beat